Harnessing the natural cellular process of autophagy to design powerful new medicines


Casma Therapeutics is harnessing the natural cellular process of autophagy to open vast new target areas for drug discovery and development. Casma uses several approaches to intervene at strategic points throughout the autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens. By boosting autophagy, Casma expects to be able to arrest or reverse the progression of lysosomal storage disorders, muscle disorders, inflammatory disorders and neurodegeneration, among other indications.


Year Invested: 2018
Location: Cambridge, MA
Visit: www.casmatx.com/

Recent News

April 13, 2019
Casma Therapeutics Named one of the Boston Business Journal’s Best Places to Work

March 26, 2019
Casma Therapeutics Establishes Scientific Advisory Board with Appointments of Leading Autophagy and Neuroscience Researchers

December 12, 2018
Casma Therapeutics Strengthens Leadership Team with Appointment of Chief Operating Officer, Vice President of People & Culture

Read More News

Associated Team Members

Cary Pfeffer, M.D.
Partner

Robert Tepper, M.D.
Partner